|
Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants & Tubular Epithelial Cell HMGB1 Promotes AKI-CKD Transition by Sensitizing Cycling Tubular Cells to Oxidative Stress: A Rationale for Targeting HMGB1 during AKI Recovery |
04/21/2023 - 12:00pm to 1:00pm |
|
The Effect of Magnesium Supplementation on Vascular Calcification in CKD: A Randomized Clinical Trial (MAGiCAL-CKD) & Clinical and Genetic Characteristics of CKD Patients with High-Risk APOL1 Genotypes |
05/19/2023 - 12:00pm to 1:00pm |
|
Ultrafiltration Rate Levels in Hemodialysis Patients Associated with Weight-Specific Mortality Risks |
06/09/2023 - 12:00pm to 1:00pm |
|
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active controlled clinical trial & Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease–Mineral and Bone Disease (CKD-MBD) Mar |
06/16/2023 - 12:00pm to 1:00pm |
|
Comparison of Cystatin C and Creatinine in the Assessment of Measured Kidney Function during Critical Illness |
06/30/2023 - 12:00pm to 1:00pm |
Facebook
X
LinkedIn
Forward